Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 17/20 | 0.45 |
| ▸ | CA1 | P00915 | 17/20 | 0.45 |
| ▸ | CA2 | P00918 | 17/20 | 0.45 |
| ▸ | CA9 | Q16790 | 17/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 12/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882066 | 0.94 | CA12 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6886825 | 0.92 | CA12 (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6881960 | 0.91 | CA12 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6889184 | 0.90 | CA12 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6880486 | 0.90 | CA12 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6887575 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6884769 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6886463 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6885703 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6885642 | 0.88 | CA12 (0.44) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |